Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04798001
Recruitment Status : Recruiting
First Posted : March 15, 2021
Last Update Posted : April 14, 2021
Sponsor:
Information provided by (Responsible Party):
Meissa Vaccines, Inc.

Brief Summary:
This study evaluates an investigational vaccine that is designed to protect humans against infection with SARS-CoV-2, the novel coronavirus causing COVID-19 disease. The investigational vaccine, MV-014-212, is a live attenuated vaccine against respiratory syncytial virus (RSV) that is expressing the spike (S) protein of SARS-CoV-2. MV-014-212 is administered as drops or a spray in the nose. Specifically, this study analyzes the safety of, and the immune response to, the vaccine when administered to healthy adults between the ages of 18 and 69 years who are seronegative to SARS-CoV-2 and have not received a prior vaccine against COVID-19.

Condition or disease Intervention/treatment Phase
Covid19 Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 130 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

This study evaluates 3 dosages of MV-014-212 in healthy adults.

Cohort A (18-55 years, inclusive) enrolls first. The first 10 participants (Group 1) receive Dosage 1. After Group 1 safety data review, 20 participants (Group 2) receive Dosage 2. After Group 2 safety data review, 50 participants (Group 3) receive Dosage 3: (i) 20 participants (Group 3a) receive a single dose; (ii) 10 participants (Group 3a) receive a 1st dose followed 2nd dose approx. 35 days after the 1st dose; (iii) 20 participants (Group 3b) receive a single dose by nasal atomizer (spray).

After review of Cohort A safety data, Cohort B (56-69 years, inclusive) enrolls. Sequential enrollment into Group 4 (10 participants; Dosage 1), Group 5 (20 participants; Dosage 2), then Group 6 (20 participants; Dosage 3) is based in each case on the preceding safety data review, as for Cohort A.

Within each group, a sentinel dosing approach is implemented as an added safety measure.

Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Phase 1, Open-Label, Dose-Escalation Study to Evaluate Tolerability, Safety, and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus Vaccine Expressing Spike Protein of SARS-CoV-2 in Healthy Adults Ages 18 - 69 Years
Actual Study Start Date : April 12, 2021
Estimated Primary Completion Date : October 31, 2022
Estimated Study Completion Date : October 31, 2022

Arm Intervention/treatment
Experimental: Cohort A / Dosage Group 1 (intranasal drops) / Single Dose
Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 1 in the form of intranasal drops on Day 1.
Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops
Single intranasal dose on Day 1, by intranasal drops

Experimental: Cohort A / Dosage Group 2 (intranasal drops) / Single Dose
Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 2 in the form of intranasal drops on Day 1.
Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops
Single intranasal dose on Day 1, by intranasal drops

Experimental: Cohort A / Dosage Group 3a (intranasal drops) / Single Dose
Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 1.
Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops
Single intranasal dose on Day 1, by intranasal drops

Experimental: Cohort A / Dosage Group 3a (intranasal drops) / Two Doses
Participants in this arm (18-55 years) will receive an intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 1. These participants will receive a second, identical dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 36.
Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops
Intranasal dose on Day 1 by intranasal drops. Followed by a second, identical dose on Day 36 by intranasal drops

Experimental: Cohort A / Dosage Group 3b (intranasal spray) / Single Dose
Participants in this arm (18-55 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of a nasal spray on Day 1.
Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray
Single intranasal dose on Day 1, by intranasal spray

Experimental: Cohort B / Dosage Group 4 (intranasal drops) / Single Dose
Participants in this arm (56-69 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 1 in the form of intranasal drops on Day 1.
Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops
Single intranasal dose on Day 1, by intranasal drops

Experimental: Cohort B / Dosage Group 5 (intranasal drops) / Single Dose
Participants in this arm (56-69 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 2 in the form of intranasal drops on Day 1.
Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops
Single intranasal dose on Day 1, by intranasal drops

Experimental: Cohort B / Dosage Group 6 (intranasal drops) / Single Dose
Participants in this arm (56-69 years) will receive a single intranasal dose of the MV-014-212 vaccine at Dosage 3 in the form of intranasal drops on Day 1.
Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops
Single intranasal dose on Day 1, by intranasal drops




Primary Outcome Measures :
  1. Solicited adverse events (AEs) [ Time Frame: Immediate post-vaccination period ]
    Frequency of solicited AEs will be measured, categorized by severity. Solicited AEs are predefined AEs that may occur after investigational vaccine administration.

  2. Unsolicited AEs [ Time Frame: Immediate post-vaccination period ]
    Frequency of unsolicited AEs will be measured, categorized by severity. Unsolicited AEs are any untoward medical occurrences in a participant administered the investigational vaccine, regardless of causal relationship to the investigational vaccine. Unsolicited AEs can include unfavorable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with the use of the investigational vaccine.

  3. Serious adverse events (SAEs) [ Time Frame: Full study duration, an average of 1 year ]
    Frequency of SAEs will be measured, categorized by vaccine-relatedness. SAEs are AEs, whether considered causally related to the investigational vaccine or not, that threaten life or result in any of the following: death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or congenital anomaly/birth defect.

  4. Medically attended adverse events (MAEs) [ Time Frame: Full study duration, an average of 1 year ]
    Frequency of MAEs will be measured, categorized by vaccine-relatedness. MAEs are AEs, whether considered causally related to the investigational vaccine or not, with unscheduled medically attended visits, such as urgent care visits, acute primary care visits, emergency department visits, or other previously unplanned visits to a medical provider. Scheduled medical visits such as routine physicals, wellness checks, 'check-ups', and vaccinations, are not considered MAEs.

  5. Change in serum neutralizing antibody titers against vaccine-encoded SARS-CoV-2 S protein [ Time Frame: Baseline through Day 29, an average of five (5) weeks ]
    Change in serum neutralizing antibody (nAb) titers against vaccine-encoded SARS-CoV-2 S protein will be measured per participant


Secondary Outcome Measures :
  1. Change in serum binding antibody concentrations against vaccine-encoded SARS-CoV-2 S protein [ Time Frame: Baseline through Day 29, an average of five (5) weeks ]
    Change in serum binding antibody concentrations against vaccine-encoded SARS-CoV-2 S protein will be measured per participant

  2. Potential vaccine virus shedding: frequency [ Time Frame: Baseline through Day 29, an average of four (4) weeks ]
    Frequency of any post-vaccination shedding of vaccine virus (as detected by viral culture) will be measured per dosage group and overall

  3. Potential vaccine virus shedding: magnitude [ Time Frame: Baseline through Day 29, an average of four (4) weeks ]
    If post-vaccination shedding of vaccine virus is detected by culture, peak viral titer (measured in plaque forming units, PFU) will be measured per dosage group and overall

  4. Potential vaccine virus shedding: duration [ Time Frame: Baseline through Day 29, an average of four (4) weeks ]
    If post-vaccination shedding of vaccine virus is detected by culture, duration of shedding (in days) will be measured per dosage group and overall



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 69 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adults ≥18 and <56 years (Cohort A) and ≥56 years and <70 years (Cohort B) as determined at the day of signing informed consent
  • SARS-CoV-2 seronegative (both IgM and IgG) at Screening
  • SARS-CoV-2 RT-PCR (nasal swab) negative at Day 1 pre-dose
  • Women of childbearing potential (WOCBP) or male subjects with partners who are WOCBP must agree to practice contraception during their study participation from the signing of informed consent for at least 3 months after the final MV-014-212 administration.
  • Written informed consent

Exclusion Criteria:

  • Diagnosis of chronic pulmonary disease (e.g. chronic obstructive pulmonary disease, asthma, pulmonary fibrosis, cystic fibrosis). Resolved childhood asthma is not exclusionary.
  • Immunocompromised state due to comorbidities or other conditions as detailed in the study protocol
  • Nasal obstruction (including due to anatomic/structural causes, acute or chronic rhinosinusitis, or other causes)
  • Receipt of any other SARS-CoV-2, other experimental coronavirus, or experimental RSV vaccine at any time prior to or during the study
  • Healthcare worker, long-term care or nursing home facility resident or employee, member of an emergency response team, or other occupation with high risk of exposure to SARS-CoV-2, and those working outside the home in customer facing occupations (e.g. waiter, cashier or store clerk, public transportation or taxi driver)
  • Positive serum pregnancy test during Screening and/or positive urine pregnancy test on Day 1
  • Breastfeeding during any period of study participation
  • Occupational or household exposure to children <5 years of age or to immunocompromised persons
  • Any medical disease or condition that, in the opinion of the PI, precludes study participation. This includes acute, subacute, intermittent or chronic medical disease or condition that would place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the subject's successful completion of this trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04798001


Contacts
Layout table for location contacts
Contact: Oliver Medzihradsky, MD MPH MS 4153108063 oliver.med@meissavaccines.com

Locations
Layout table for location information
United States, Kansas
Johnson County Clin-Trials Recruiting
Lenexa, Kansas, United States, 66219
Contact: Mazen Zari, MS.cs, RRT    913-825-4400    mzari@jcct.com   
Principal Investigator: Carlos Fierro, MD         
United States, Maryland
Meridian Clinical Research Not yet recruiting
Rockville, Maryland, United States, 20854
Contact: Juliana DeVito, CCRC    240-698-2800 ext 504    jdevito@mcrmed.com   
Principal Investigator: Shishir K Khetan, MD         
Sponsors and Collaborators
Meissa Vaccines, Inc.
Investigators
Layout table for investigator information
Study Director: Oliver Medzihradsky, MD MPH MS Meissa Vaccines, Inc.
Publications:
Layout table for additonal information
Responsible Party: Meissa Vaccines, Inc.
ClinicalTrials.gov Identifier: NCT04798001    
Other Study ID Numbers: MV-101
First Posted: March 15, 2021    Key Record Dates
Last Update Posted: April 14, 2021
Last Verified: April 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Meissa Vaccines, Inc.:
live attenuated vaccine
safety
immunogenicity
Phase 1 clinical trial
adult
seronegative
Additional relevant MeSH terms:
Layout table for MeSH terms
Vaccines
Immunologic Factors
Physiological Effects of Drugs